Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 1/6/22 Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference 12/31/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/17/21 Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development 11/17/21 Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors 11/3/21 Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments 11/2/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences 10/29/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/27/21 Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021 10/13/21 Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last » Displaying 81 - 90 of 788 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 1/6/22 Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference 12/31/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/17/21 Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development 11/17/21 Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors 11/3/21 Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments 11/2/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences 10/29/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/27/21 Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021 10/13/21 Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last » Displaying 81 - 90 of 788